Browse EX-10 agreements

FORM OF RETENTION BONUS AGREEMENT

THIS RETENTION BONUS AGREEMENT (the “Agreement”), entered into by and between enGene USA, Inc. (“the Company”) and [NAME] (the “Employee”), shall be effective _____, 2026.

WHEREAS, the Company has determined that it is appropriate to award a retention bonus to the Employee whose continued service is particularly important to the success of the Company.

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

1.

…

June 15, 2026

By Email

Lee G. Giguere

RE: Separation Agreement & General Release

Dear Lee:

This letter of agreement and general release (“Agreement”) confirms our mutual agreement regarding the terms and conditions of your separation from employment with enGene USA, Inc. (“enGene” or the “Company”). You and the Company agree as follows:

1.

Separation Date. Your last day of employment with the Company will be July 15, 2026 (“Separation Date”). You will receive your salary at your regular rate of pay through your Separation Date. Your employment and your participation in the Company’s employee benefit plans and programs will terminate on your Separation Date.

2.

…

Exhibit 10.9(a)

FORM OF RETENTION BONUS AGREEMENT

THIS RETENTION BONUS AGREEMENT (the “Agreement”), entered into by and between enGene USA, Inc. (“the Company”) and NAME (the “Employee”), shall be effective _____, 2026.

WHEREAS, the Company has determined that it is appropriate to award a retention bonus to the Employee whose continued service is particularly important to the success of the Company.

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

1.

…

FOR CANADIAN EMPLOYEES Exhibit 10.9(b)

FORM OF RETENTION BONUS AGREEMENT

THIS RETENTION BONUS AGREEMENT (the “Agreement”), entered into by and between enGene Inc. (“the Company”) and NAME (the “Employee”), shall be effective June ____, 2026.

WHEREAS, the Company has determined that it is appropriate to award a retention bonus to the Employee whose continued service is particularly important to the success of the Company.

NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows:

1.

…

ENGENE HOLDINGS INC.

AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN

RESTRICTED SHARE UNIT AGREEMENT

This RESTRICTED SHARE UNIT AGREEMENT (the “Agreement”), dated as of [●](the “Date of Grant”), is delivered by enGene Therapeutics Inc., a company organized under the laws of British Columbia, Canada and formerly known as enGene Holdings Inc. (the “Company”), to [●](the “Participant”).

RECITALS

The enGene Holdings Inc. Amended and Restated 2023 Equity Incentive Plan (the “Plan”) provides for the grant of restricted Share Units in accordance with the terms and conditions of the Plan. The Committee has decided to make this grant of restricted Share Units as an inducement for the Participant to promote the best interests of the Company and its shareholders in the future. This grant of restricted Share Units solely relates to the Participant’s services to the Company during the period described in Section 3 and does not provide any compensation to the Participant for any services rendered by the Participant prior to the Date of Grant, nor shall this Agreement be interpreted in such

…

EMPLOYMENT AGREEMENT FOR KATHLEEN RICHTON

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between enGene USA, Inc., its successors and assigns (the “Company”) and Kathleen Richton (the “Employee”) as of the date first written below.

WHEREAS, the Company desires to promote the Employee to serve as the Company’s Senior Vice President, Finance and the Employee desires to serve in such capacity on behalf of the Company.

NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, the Company and the Employee hereby agree as follows:

1.

Employment.

(a)

…

ENGENE HOLDINGS INC.

AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN

NONQUALIFIED STOCK OPTION GRANT AGREEMENT

This NONQUALIFIED STOCK OPTION GRANT AGREEMENT (the “Agreement”), dated as of [●] (the “Date of Grant”), is delivered by enGene Therapeutics Inc., a company organized under the laws of British Columbia, Canada and formerly known as enGene Holdings Inc. (the “Company”), to [●] (the “Participant”).

RECITALS

The enGene Holdings Inc. Amended and Restated 2023 Equity Incentive Plan (the “Plan”) provides for the grant of stock options to purchase common shares of the Company (“Company Shares”). The Committee has decided to make this nonqualified stock option grant as an inducement for the Participant to promote the best interests of the Company and its shareholders. This Agreement is made pursuant to the Plan and is subject in its entirety to all applicable provisions of the Plan. Capitalized terms used herein and not otherwise defined will have the meanings set forth in the Plan.

1.

…

Exhibit 10.1

INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10)(iv) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND CUSTOMARILY AND ACTUALLY TREATED BY THE REGISTRANT AS PRIVATE OR CONFIDENTIAL.

OTHER TRANSACTION AGREEMENT

BETWEEN

Rigetti & Co, LLC

775 Heinz Avenue, Berkeley, CA 94710

AND

United States Department of Commerce

1401 Constitution Avenue, NW, Washington, DC 20230

CONCERNING

ADVANCED MICROELECTRONICS RESEARCH AND DEVELOPMENT IN THE U.S.

FAIN:		80NANB26T203
Award Amount:		$100,000,000
Authorities:		15 U.S.C. § 4656(c)(2)(A)
		15 U.S.C. § 4659(a)(1)
Award Date:		September 4, 2026

…

SECURITIES ISSUANCE AGREEMENT

THIS SECURITIES ISSUANCE AGREEMENT (this “Agreement”), is made as of September 8, 2026, by and between Rigetti Computing, Inc., a Delaware corporation (the “Company”), and the United States Department of Commerce (the “Department”).

WHEREAS, the Department and Rigetti & Co, LLC, a wholly-owned subsidiary of the Company (the “Awardee”), are parties to that certain Other Transaction Agreement, dated September 4, 2026 (the “Award Agreement”), setting forth, among other things, certain terms and conditions pursuant to which the Department agreed to issue to the Awardee an award (the “Award”) administered pursuant to the CHIPS Act; and

WHEREAS, in order to induce the Department to enter into the Award Agreement, the Company has agreed, subject to the terms and conditions set forth herein, to issue to the Department such number of Shares (as defined below) set forth in Item 1 of Exhibit A.

…

June 17, 2026

Keith Lane

Dear Keith:

Kiara Pharmaceuticals, Inc. (the "Company'') is pleased to offer you employment with a start date of September 1, 2026 (the "Start Date"). Your role shall be to serve as Executive Vice President, Head of Clinical Development and Regulatory Affairs of the Company. This letter is intended to summarize some of the terms of your employment. We refer you to the policies, plans and practices of the Company for more details on the terms and conditions of your employment.

Your employment is considered "at will"; both you and the Company have the right to terminate your employment at any time for any reason. This letter does not constitute, and shall not be construed as, creating a contract or promise of employment for any set period of time.

…

Execution Copy FAIN: 80NANB26T200 Page 1 of 51 OTHER TRANSACTION AGREEMENT BETWEEN D-Wave Quantum Inc. 2650 E. Bayshore Road, Palo Alto, CA 94303 AND United States Department of Commerce 1401 Constitution Avenue, NW, Washington, DC 20230 CONCERNING ADVANCED MICROELECTRONICS RESEARCH AND DEVELOPMENT IN THE U.S. FAIN: 80NANB26T200 Award Amount: $100,000,000 Authorities: 15 U.S.C. § 4656(c)(2)(A) 15 U.S.C. § 4659(a)(1) 15 U.S.C. § 4656(d) Award Date: September 4, 2026 Pursuant to the Authorities specified above, this Other Transaction Agreement is entered into as of the Award Date specified above, between D-Wave Quantum Inc. (the “Awardee”) and the U.S. Department of Commerce (the “Department”). D-WAVE QUANTUM INC. UNITED STATES DEPARTMENT OF COMMERCE By: /s/ Alan Baratz By: /s/ Bill Frauenhofer Name: Alan Baratz Name: Bill Frauenhofer Title: Director Title: Executive Director Semiconductor Innovation and Investment Certain identified information has been excluded from the exhibit because it (i) is not material and (ii) is the type that the registrant treats as private or confidential.

…

---

Exhibit 10.1

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT by and between Anteris Technologies Global Corp., a Delaware corporation (the “Company”), and Brent Moen (“Executive”), is dated as of the 4th day of September, 2026 (this “Agreement”).

WHEREAS, the Company wishes to employ Executive on the terms and conditions, and for the consideration, hereinafter set forth, and Executive desires to be employed by the Company on such terms and conditions and for such consideration.

NOW, THEREFORE, in consideration of the promises provided for in this Agreement, the Company and Executive hereto agree as follows:

…